01867nas a2200769   4500000000100000000000100001000000100002008004100003653003600044653002100080653001100101653003800112653002000150653001300170653001300183653001500196653001800211653001700229100001400246700002300260700001400283700001900297700001700316700001400333700001300347700001600360700001400376700001500390700001600405700001200421700001400433700001300447700001700460700001600477700001500493700001300508700001500521700001500536700001500551700001200566700001300578700001600591700001500607700001600622700001700638700001300655700001500668700002200683700001300705700001400718700001300732700001600745700001700761700001900778700001300797700001300810700001500823700001300838700001300851700001400864700001500878245015600893250001501049300001201064490000701076020001401083       2022                            d10a*COVID-19/complications/therapy10aCOVID-19 Testing10aHumans10aPatient Reported Outcome Measures10aQuality of Life10aSyndrome10aCovid-1910aimmunology10apublic health10atherapeutics1 aS. Haroon1 aK. Nirantharakumar1 aS. Hughes1 aA. Subramanian1 aO. Aiyegbusi1 aE. Davies1 aP. Myles1 aT. Williams1 aG. Turner1 aJ. Chandan1 aC. McMullan1 aJ. Lord1 aD. Wraith1 aK. McGee1 aA. Denniston1 aT. Taverner1 aL. Jackson1 aE. Sapey1 aG. Gkoutos1 aK. Gokhale1 aE. Leggett1 aC. Iles1 aC. Frost1 aG. McNamara1 aA. Bamford1 aT. Marshall1 aD. Zemedikun1 aG. Price1 aS. Marwaha1 aN. Simms-Williams1 aK. Brown1 aA. Walker1 aK. Jones1 aK. Matthews1 aJ. Camaradou1 aM. Saint-Cricq1 aS. Kumar1 aY. Alder1 aD. Stanton1 aL. Agyen1 aM. Baber1 aH. Blaize1 aM. Calvert00aTherapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study)  a2022/04/28  ae0604130 v12  a2044-6055